66 Comments
 

YTD Dealogic league tables (through 9/10/2013):

Global M&A Volume:

GS - $114bn JPM - $103bn MS - $85bn Barclays - $66bn BAML - $26bn UBS - $10bn CS - $7bn Citi - $7bn Jefferies - $6bn

All products (fees):

JPM - $459mm GS - $354mm BAML - $287mm MS - $242mm Barclays - $232mm Citi - $153mm CS - $152mm Jefferies - $109mm DB - $104mm UBS - $93mm

In terms of culture, most/all HC groups are relative sweatshops. GS might be better than others though. It's a broad space that doesn't really pigeonhole you so exit opps should be good if you're at a good bank. Comp doesn't matter at the junior level.

It's definitely a great space to be in at the moment.

 

So, i'll preface by saying that I'm in heathcare (M&A). Healthcare is a very defensible industry (less suscptible to market shocks), so you'll get consistent deal flow at any BB/boutique since your client base likes to spread deals/fees around. If you go Citi/BAML/JP/MS/Barc/Lazard/GS, you'll get good experience and will have plenty of buyside opportunities.

The question you should really be asking, however, is within what realms of healthcare are these banks strongest. There are four main verticals in HC (pharma/med-tech/providers/HCIT), and there's even more diversification within those verticals. So figure out where groups stand in terms of each vertical and where you see yourself fitting in.

That brings me to my next point: consider the group culture. It's a very, very important step you should conduct during your due diligence. Figure out where you see yourself fitting in. Because of the space being so verticalized, you'll get worked, no matter where you go. Just go some place where you like the people, provided again that it's one the banks I mentioned.

 

Thanks for the SB. Now, regarding exits:

The great thing about the space is a. you get a variety of deals/transactions (IPOs, RMTs, debt offerings, M&A, rest., etc etc etc.). For that reason your ability to model out complex and differing scenarios is well-developed by the time you're looking to leave. So that's why PE firms love HC guys.

Additionally, if you consider the space, remember that I mentioned the space as being highly verticalized. You're going to get WORKED in healthcare because of how many players exist in all four verticals (unlike, say, power/NatRes). For that reason, there's a ton of investment opportunity so you'll see that there are more funds focused on Tech and HC than possibly any other space. Consumer is another loved one among PE firms.

Anyways, TL;DR: the opportunities to move PE/Mega Funds exist. Wherever you end up is ultimately up to you. I've seen analysts move to Warburg/KKR/Carlyle and others, to the peace corps. Where they ended up has never once surprised me. So again go to a group where you fit in. The rest is up to you.

 

Healthcare is miserable, don't do it! I was a healthcare analyst and I spent way more time than other analysts researching industry related "stuff." This was in addition to the normal responsibilities of an M&A analyst. If you aren't interested in becoming a healthcare finance professional as a career, i'd say get out!

CompBanker’s Career Guidance Services: https://www.rossettiadvisors.com/
 

I know a few banks that have focus-areas in the biotech space, but those groups are brutal. I've done a little bit of work for my bank's HC group, and it is not enjoyable. Just to echo what CompBanker said above, there is so much extra research that goes into a pitch/deal on the HC side, and unless you're a huge fan of the HC industry, it is boring, slow and tedious. Not to mention, a lot of MM HC firms aren't profitable and are in the testing stage, so the valuation on these guys can be pretty one-dimensional (predominantly revenue-driven) and doesn't really allow for much wiggle room.

I think having background in science (whether it be educational or actual work experience) can be really helpful in the space, as it makes understanding information and gaining knowledgability in the industry a helluva lot easier... plus, you know it interests you.

 
jimbrowngoUI know a few banks that have focus-areas in the biotech space, but those groups are brutal. I've done a little bit of work for my bank's HC group, and it is not enjoyable. Just to echo what CompBanker said above, there is so much extra research that goes into a pitch/deal on the HC side, and unless you're a huge fan of the HC industry, it is boring, slow and tedious. Not to mention, a lot of MM HC firms aren't profitable and are in the testing stage, so the valuation on these guys can be pretty one-dimensional (predominantly revenue-driven) and doesn't really allow for much wiggle room.

I think having background in science (whether it be educational or actual work experience) can be really helpful in the space, as it makes understanding information and gaining knowledgability in the industry a helluva lot easier... plus, you know it interests you.

Mind letting us know what banks those are? I really don't consider any other industry-focus as interesting as biotech. I'd think the research into products/innovations would be fascinating. I don't have a background in molecular analysis or anything like that, but I enjoy learning and understanding the applications for products in this space.

 

Is there anywhere someone could kindly point me to learn more about industry-specific techniques used in HC IB (esp. services and facilities, if at all possible)? I'm looking for a long term career in HC finance, don’t care about workload. I've read industry research everywhere I can find it, done tons of generic modeling (ie modeling programs on my own, some fig in practice), but there's not much specifically geared towards HC IB...thanks so much to anyone.

 
Best Response

My two cents about Healthcare is that it is a very niche space. Some of what others have said is true in that the research can be pretty tedious, especially if you don't like science.

Also, most BB Healthcare groups are subdivided into several verticals, usually life sciences, Medtech and services. Life Science and Medtech is where you will find most of the innovative companies such as Pharma, Biotech and Medical devices. While these are the coolest companies, they also tend to do only M&A and equity; not a whole lot of debt. Services include facilities and other businesses like PBM's. THese are much more traditional businesses with steadier cash-flows, tangible assets and a lot of debt financing.

Depending on what you get into, the upside of a Healthcare experience is that by the time you're a bit more senior, you'll be able to speak in a language that nobody else will understand (and so have a job that not many people can do). It is probably the coverage group that has THE most domain-specific knowledge of any I know of, except for perhaps FIG.

 

DB HC = sweatshop

-9am - 2am average -Endless company profiles -Less modeling (farmed out to product groups) -Bad exit ops without connections -Good dealflow

 

JPM dominates by far - this has been discussed before.

HC is a balance-sheet based business where the top fees go to banks who can take on the most risk in terms of loans/revolvers, e.g. a traditional banking model.

Calm down.
 

Are you more interested in healthcare IT/services or pharma? Impacts the response.

"If you want to succeed in this life, you need to understand that duty comes before rights and that responsibility precedes opportunity."
 

For now I am interested in all. I have more biotech/pharma experience and it's definitely "sexier" and more exciting but I am reading and really getting interested in services/devices/tech. most my HC experience this year will most likely be in services anyways, so i am not differentiating for now (especially since I figure HC PE is already a small subset anyways).

Also I kind of assumed most of HC PE is services based by the nature of PE? wouldn't make as much sense to do a biotech LBO..

 
bankbanker101

Industrials is balanced sheet based. HC is much like TMT, there's a ton of diversity in deals and clients. It's less reliant on debt, despite every bank offering up revolvers to get a slice of future fees.

No offense, you are right with respect to some HC sectors - I actually work in HC investment banking and I can tell you that while the industry is large, the top deals are won through balance sheet-based lending and less focused on extra M&A and advisory work done. You'll have one-offs like when BBH advised TFX on the LMA acquisition, but those are only for the MM deals.

MM HC is more of a crapshoot, while the BB and largest deals are done by the top lenders. If the firm screws their top lenders out of fees, then they'll simply drop out due to the excessive BS risk.

Case in point - CYH acquisition of HMA.

Also, your comment about banks offering revolvers to get a slice of future fees is correct, but you forgot to mention term loans which, in combination with revolvers, can push a bank to the top of the total commitments table.

HC is heavily dependent on debt, especially the REIT sector - that's the only way they raise capital, and recently with debt being so cheap, that's all they've been doing. Sure they'll issue equity, but not with one of the hottest debt markets we've seen in a while.

Calm down.
 

Quia in hic dolor aut corrupti. Corporis accusantium exercitationem autem illo voluptas. Dolore cum et qui odio. Et dolore ab sint debitis fugiat officia autem.

Qui debitis eius a at pariatur provident cumque. Quis quaerat et repudiandae quia quo. Est aut nostrum iste nesciunt pariatur possimus quod. Consequatur quidem ullam hic molestias explicabo impedit. Distinctio nihil officia illo.

Est nostrum ut assumenda esse animi ex beatae a. Consequuntur est quo non et. Perferendis et atque dicta reprehenderit.

Fugit recusandae praesentium adipisci cupiditate error aut. Voluptatibus quia et fugiat consectetur. Ea ut aspernatur reprehenderit. Quisquam ducimus eos et suscipit quidem qui. Sed officia dolores ut natus laborum rerum excepturi. Quasi harum quaerat similique quod quas. Ut earum nostrum vitae quis pariatur aut recusandae.

 

Totam ratione dolores ipsum soluta voluptas ea et. Perspiciatis labore ipsa pariatur illum aut repudiandae dicta. Consequatur beatae et nam magni nemo omnis sed inventore. Commodi doloribus corporis tempora. Laboriosam error quibusdam dolorem veniam odit temporibus eum.

Eius ut harum aut nihil. Voluptas et et praesentium quia placeat rem quidem. Ad aliquam dolorum molestias qui alias. Ut porro rem dolor ipsa cupiditate alias et itaque. Quam sit eos dolore quasi blanditiis amet.

Nihil corrupti repellendus quam explicabo cupiditate voluptatem provident. Nihil nemo repellendus exercitationem occaecati. Dolor magni accusamus veniam atque labore modi. Veritatis veritatis officia voluptas sequi sit. Rerum sit magnam eos.

 

At hic dolor facilis sunt voluptas consequatur. Sequi reiciendis qui possimus et possimus accusamus fuga. Et corrupti rerum dolorum cupiditate. Dolorum culpa natus et et mollitia eius consequatur.

Fuga pariatur et magnam deserunt. Ut aut et sapiente et perspiciatis. Quam sed voluptatem id exercitationem doloribus omnis.

Et dolores sequi dolores itaque. Ad tenetur omnis sit reiciendis sunt et provident.

Reprehenderit tempora ratione laudantium qui quae et explicabo assumenda. Earum ducimus laudantium rem cumque velit. Occaecati voluptatem ea sed magni magni. Aut tempora blanditiis et asperiores facere. Suscipit vero sit quis non libero corrupti. Repellendus id est accusamus velit aut id.

 

Sunt id omnis voluptates vitae molestias pariatur rerum. Ut consequuntur facere minus quas et libero autem. Consectetur beatae nesciunt et quidem vel. Eum ad ipsa rerum iste soluta et molestias. Officia debitis molestias quia voluptas necessitatibus.

Praesentium perspiciatis quo aspernatur et. Nesciunt aut odit eos quidem quis voluptatem. Vitae rerum qui quaerat qui voluptas ea in similique.

Et doloremque qui reprehenderit voluptate aliquam enim. Tempora quam non dolor id in. Mollitia delectus recusandae quaerat magnam tempore tenetur. Suscipit quidem dolor consectetur fuga consectetur officiis in. Fuga officiis rem velit iure non et. Quia est delectus dignissimos voluptate quia autem officia tempore.

Et ipsam doloribus adipisci cum. Provident neque doloribus nostrum.

Career Advancement Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.3%
  • Guggenheim Partners 01 97.8%
  • Morgan Stanley 07 97.2%

Overall Employee Satisfaction

July 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Evercore No 98.9%
  • Morgan Stanley 01 98.3%
  • Banco Santander 02 97.7%
  • BMO Capital Markets 12 97.2%

Professional Growth Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 06 98.3%
  • Goldman Sachs 01 97.8%
  • JPMorgan 01 97.2%

Total Avg Compensation

July 2026 Investment Banking

  • Vice President (16) $429
  • Associates (46) $258
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (14) $159
  • 1st Year Analyst (80) $150
  • Intern/Summer Analyst (73) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
BankonBanking's picture
BankonBanking
99.0
3
Secyh62's picture
Secyh62
99.0
4
kanon's picture
kanon
99.0
5
CompBanker's picture
CompBanker
98.9
6
Betsy Massar's picture
Betsy Massar
98.9
7
dosk17's picture
dosk17
98.9
8
GameTheory's picture
GameTheory
98.9
9
DrApeman's picture
DrApeman
98.9
10
Jamoldo's picture
Jamoldo
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”